Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 124, Issue 1, Pages 40-46Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI69739
Keywords
-
Categories
Funding
- Henry and Marilyn Taub Foundation
- German Research Foundation
- DFG [SPP 1463, Lu 429/7-1, C04]
Ask authors/readers for more resources
The term epigenetics refers to the heritable changes in gene expression that are not associated with a change in the actual DNA sequence. Epigenetic dysregulation is linked to the pathogenesis of a number of malignancies and has been studied extensively in myelodysplastic syndromes and acute myeloid leukemia. DNA methylation is frequently altered in cancerous cells and likely results in transcriptional silencing of tumor suppressor genes. Re-expression of these genes by inhibition of the DNA methyltransferases has been successful in the treatment of benign and malignant disease. In this Review, we discuss the clinical development of demethylating agents in hematology, with a focus on azacitidine and decitabine.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available